4 studies found for:    12075054 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Recruiting Phase II Trial of Alemtuzumab (Campath) and Dose-Adjusted EPOCH-Rituximab (DA-EPOCH-R) in Relapsed or Refractory Diffuse Large B-Cell and Hodgkin Lymphomas
Conditions: Hodgkin Lymphoma;   Diffuse Large B-Cell Lymphoma
Interventions: Drug: Cylcophosphamide;   Drug: Etoposide;   Drug: Alemtuzumab;   Drug: Doxorubicin;   Drug: Prednisone;   Drug: Filgrastim;   Drug: Rituximab;   Drug: Vincristine
2 Recruiting Tissue Collection for Studies of Lymph Cancer
Conditions: Hodgkin Disease;   Lymphoma, Non-Hodgkin;   Multiple Myeloma;   Lymphomatoid Granulomatosis;   Leukemia-Lymphoma, Adult T-Cell
Intervention:
3 Completed Genetic Determinations for Side Effects and Response Rate for Patients Receiving Chemotherapy With Diffuse Large Cell Lymphoma
Conditions: Lymphoma;   Diffuse Large Cell
Intervention: Procedure: Blood draw
4 Withdrawn MLN4924 Compared With MLN4924 Plus Chemotherapy for Large B-cell Lymphoma
Conditions: Lymphoma, Diffuse Large-Cell B-cell;   Diffuse, Large B-cell Lymphoma;   Lymphoma, Diffuse Large-Cell;   Large-Cell Lymphoma, Diffuse
Interventions: Drug: MLN4924;   Drug: Etoposide;   Drug: Prednisone;   Drug: Vincristine;   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Rituximab;   Drug: Filgrastim

Indicates status has not been verified in more than two years